English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
हिन्दी
日本語
By Mauro Orru
Novartis’s generics-and-biosimilars division Sandoz entered into an agreement with Samsung Bioepis to commercialize in Europe and North America an antibody medication for the treatment of autoimmune disorders such as Crohn’s disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
The company said Monday that the development and commercialization agreement handed Sandoz exclusive rights to commercialize biosimilar SB17 ustekinumab in the U.S., Canada, the European Economic Area, Switzerland, and the U.K. Sandoz said other specific terms of the agreement are confidential.
“It will further strengthen our immunology patient offering and means we now have five potential high-value upcoming biosimilar launches over the next few years,” said Sandoz Chief Executive Richard Saynor.
Write to Mauro Orru at [email protected]; @MauroOrru94
Read the full article here